Skip to main content
NVDA-1.19%AAPL+0.67%GOOGL-2.28%MSFT-0.48%AMZN-0.82%TSM-0.83%SPCX-3.86%AVGO-1.13%META+0.20%TSLA-1.97%SKHY+7.05%MU-3.05%BRK-B+0.18%LLY+0.02%JPM+0.34%AMD+3.04%WMT-0.21%V-0.34%XOM+2.24%ASMLa-2.91%JNJ-0.76%INTC+1.69%MA-0.59%0700.HK-1.94%ORCL-0.50%1398.HK+0.79%BAC+0.45%ABBV+0.88%CSCO+0.24%CVX+1.91%COST-0.83%LRCX-1.43%KO-0.92%CAT-0.84%AMAT-0.83%0005.HK-0.78%AP2d-2.69%UNH-1.94%DELL+0.29%HSBA.L-1.34%MS-0.42%PG-2.02%GE-2.83%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.96%HD-1.04%GS-0.75%0939.HK+1.66%NZDJPY-2.62%AUDJPY-1.87%CHFJPY-1.71%NZDCAD-1.45%GBPJPY-1.39%EURJPY-1.38%NZDUSD-1.37%EURNZD+1.28%USDJPY-1.28%GBPNZD+1.24%CADJPY-1.19%NZDCHF-0.95%USDZAR+0.95%USDSEK+0.88%USDNOK+0.87%AUDNZD+0.78%AUDCAD-0.72%EURZAR+0.67%USDTHB+0.61%USDMXN+0.61%AUDUSD-0.61%EURSEK+0.60%GBPZAR+0.59%EURNOK+0.59%AUDSGD-0.54%USDPLN+0.53%AUDDKK-0.52%CADCHF+0.51%EURAUD+0.50%CHFSEK+0.49%CHFNOK+0.48%GBPAUD+0.47%USDCHF+0.45%GBPTRY+0.41%NOKJPY-0.41%NZDSGD-0.38%GBPHKD+0.32%EURCHF+0.32%GBPCHF+0.30%EURHKD-0.30%GBPMXN-0.28%USDDKK+0.28%USDSGD+0.27%EURPLN+0.25%GBPCAD-0.22%EURCAD-0.20%SGDJPY+0.19%EURCNH-0.17%AUDCHF-0.17%USDILS+0.16%CHFSGD-0.12%GBPUSD-0.12%EURUSD-0.12%USDTRY+0.11%USDCNH+0.09%GBPSGD-0.09%USDCAD-0.08%PLNJPY-0.07%NZDMXN-0.06%AUDNOK+0.06%USDCOP-0.04%EURCZK-0.03%EURGBP+0.03%EURSGD-0.01%USDHKD+0.01%EURDKK0.00%XPTUSD-4.86%XAGUSD-4.32%GAGUSD-4.32%HG1-4.09%UKOIL+3.27%USOIL+3.15%COFFEE-2.45%GAUUSD-1.17%XAUUSD-1.17%SUGAR+1.15%COTTON+0.60%XNGUSD-0.29%BTCUSD-1.81%ETHUSD-2.01%USDTUSD-0.02%XRPUSD-2.77%SOLUSD-2.07%TRXUSDT-0.17%ZECUSDT-5.51%DOGEUSD-2.88%XMRUSDT-2.04%LINKUSD-1.08%XLMUSD-2.10%BCHUSDT-8.60%LTCUSD-2.09%UNIUSD-4.73%TONUSD+24.88%HBARUSDT-2.37%SUIUSD-2.75%TAOUSDT-4.55%AAVEUSD-3.25%DOTUSDT-2.63%ICPUSDT-1.30%ONDOUSDT-2.87%WLDUSDT-2.43%ATOMUSDT-3.41%ARBUSDT-1.04%JUPUSDT-3.82%INJUSDT-3.30%STXUSDT-3.80%FETUSDT-3.24%TIAUSDT-1.65%SEIUSDT-3.91%PYTHUSDT-1.17%IMXUSDT-3.06%WIFUSDT-4.40%GRTUSDT-3.82%OPUSDT-3.00%IOTAUSDT-3.80%POLUSDT-7.08%AXSUSDT-2.57%FARTCOINUSDT-3.67%EOSUSDT-1.86%DYDXUSDT-0.24%ORDIUSDT-0.69%GALAUSDT-4.78%NOTUSDT-0.68%RONINUSDT-2.64%NVDA-1.19%AAPL+0.67%GOOGL-2.28%MSFT-0.48%AMZN-0.82%TSM-0.83%SPCX-3.86%AVGO-1.13%META+0.20%TSLA-1.97%SKHY+7.05%MU-3.05%BRK-B+0.18%LLY+0.02%JPM+0.34%AMD+3.04%WMT-0.21%V-0.34%XOM+2.24%ASMLa-2.91%JNJ-0.76%INTC+1.69%MA-0.59%0700.HK-1.94%ORCL-0.50%1398.HK+0.79%BAC+0.45%ABBV+0.88%CSCO+0.24%CVX+1.91%COST-0.83%LRCX-1.43%KO-0.92%CAT-0.84%AMAT-0.83%0005.HK-0.78%AP2d-2.69%UNH-1.94%DELL+0.29%HSBA.L-1.34%MS-0.42%PG-2.02%GE-2.83%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.96%HD-1.04%GS-0.75%0939.HK+1.66%NZDJPY-2.62%AUDJPY-1.87%CHFJPY-1.71%NZDCAD-1.45%GBPJPY-1.39%EURJPY-1.38%NZDUSD-1.37%EURNZD+1.28%USDJPY-1.28%GBPNZD+1.24%CADJPY-1.19%NZDCHF-0.95%USDZAR+0.95%USDSEK+0.88%USDNOK+0.87%AUDNZD+0.78%AUDCAD-0.72%EURZAR+0.67%USDTHB+0.61%USDMXN+0.61%AUDUSD-0.61%EURSEK+0.60%GBPZAR+0.59%EURNOK+0.59%AUDSGD-0.54%USDPLN+0.53%AUDDKK-0.52%CADCHF+0.51%EURAUD+0.50%CHFSEK+0.49%CHFNOK+0.48%GBPAUD+0.47%USDCHF+0.45%GBPTRY+0.41%NOKJPY-0.41%NZDSGD-0.38%GBPHKD+0.32%EURCHF+0.32%GBPCHF+0.30%EURHKD-0.30%GBPMXN-0.28%USDDKK+0.28%USDSGD+0.27%EURPLN+0.25%GBPCAD-0.22%EURCAD-0.20%SGDJPY+0.19%EURCNH-0.17%AUDCHF-0.17%USDILS+0.16%CHFSGD-0.12%GBPUSD-0.12%EURUSD-0.12%USDTRY+0.11%USDCNH+0.09%GBPSGD-0.09%USDCAD-0.08%PLNJPY-0.07%NZDMXN-0.06%AUDNOK+0.06%USDCOP-0.04%EURCZK-0.03%EURGBP+0.03%EURSGD-0.01%USDHKD+0.01%EURDKK0.00%XPTUSD-4.86%XAGUSD-4.32%GAGUSD-4.32%HG1-4.09%UKOIL+3.27%USOIL+3.15%COFFEE-2.45%GAUUSD-1.17%XAUUSD-1.17%SUGAR+1.15%COTTON+0.60%XNGUSD-0.29%BTCUSD-1.81%ETHUSD-2.01%USDTUSD-0.02%XRPUSD-2.77%SOLUSD-2.07%TRXUSDT-0.17%ZECUSDT-5.51%DOGEUSD-2.88%XMRUSDT-2.04%LINKUSD-1.08%XLMUSD-2.10%BCHUSDT-8.60%LTCUSD-2.09%UNIUSD-4.73%TONUSD+24.88%HBARUSDT-2.37%SUIUSD-2.75%TAOUSDT-4.55%AAVEUSD-3.25%DOTUSDT-2.63%ICPUSDT-1.30%ONDOUSDT-2.87%WLDUSDT-2.43%ATOMUSDT-3.41%ARBUSDT-1.04%JUPUSDT-3.82%INJUSDT-3.30%STXUSDT-3.80%FETUSDT-3.24%TIAUSDT-1.65%SEIUSDT-3.91%PYTHUSDT-1.17%IMXUSDT-3.06%WIFUSDT-4.40%GRTUSDT-3.82%OPUSDT-3.00%IOTAUSDT-3.80%POLUSDT-7.08%AXSUSDT-2.57%FARTCOINUSDT-3.67%EOSUSDT-1.86%DYDXUSDT-0.24%ORDIUSDT-0.69%GALAUSDT-4.78%NOTUSDT-0.68%RONINUSDT-2.64%
UP

UroGen Pharma Ltd. (URGN)

NASDAQ • Healthcare

$45
+$1.17 (+2.7%)
Market open

Last close at September 9, 2026 at 20:00 UTC

Open$43.82
Previous Close$45
Day Range$43.77 - $47.06
Avg. Volume (3M)883.8K
Market Cap$2.1B
52 Week Range
$15.86$50.81
Next EarningsIn 56 daysNov 5, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$72.4M100%
Gross Profitminus cost of goods$65.8M91%
Operating Incomeminus R&D and overhead$111K0%

In plain terms: out of every $100 in revenue, UroGen Pharma Ltd. currently loses $20.

Fundamentals & Financials

Revenue (TTM)
$188.7M
Net Income (TTM)
-$97.6M
EPS (TTM)
-$1.98
ROA (TTM)
-38.65%
Current Ratio
3.8

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-4.2%Q1 2026-$0.54
+16.1%Q2 2026-$0.47
-5.7%Q3 2026-$0.28
Next

Nov 5

in 56 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -5.7%

UroGen Pharma’s revenue topped consensus but EPS trailed expectations in the second fiscal quarter of 2026, reported August 5, 2026, as sales growth outpaced the bottom-line improvement. Revenue rose 199.2% to about $72.5 million (up from about $24.2 million a year ago) and topped the $63.5 million estimate (+14%), while EPS of -$0.28 trailed the -$0.27 estimate (difference -$0.02) but improved from -$1.05 a year ago. Profitability was reflected in gross profit of roughly $65.9 million alongside gross margin of ~91%, and net income narrowed to a loss of about $14.4 million (from a loss of roughly $49.9 million a year ago), a +71.3% year-over-year change. Cash generation remained negative, with negative operating cash flow of about $33.0 million. For the next period, consensus calls for EPS of $0.10 on revenue of $90.6 million.

View full earnings history

About UroGen Pharma Ltd.

UroGen Pharma Ltd. develops and commercializes treatments for urothelial and specialty cancers. Listed on NASDAQ as URGN, it operates as a biotechnology company built around localized drug delivery and cancer therapeutics, and it generated $109.8 million of revenue in FY2025.

Name
UroGen Pharma Ltd.
CEO
Elizabeth Barrett
Website
www.urogen.com
Industry
Healthcare
Year Founded
2004
Employees
300

Today's Snapshot

AI-generated

URGN ended yesterday 2.7% up at 45.00. Jefferies, an analyst firm, kept its UroGen Pharma rating after data on a rival drug.

Trading Volume

Above 10d avg 697.1K

1M

vs S&P 500 Today

Strong Outperformance

+3.18%

Updated: September 10, 2026 at 12:21 UTC

Technical Indicators

5 Buy3 Neutral0 Sell
URGN trades at 45.00 with a subdued trend environment indicated by an ADX around 20, while short-term moving averages sit slightly below price and longer-term averages remain well below, pointing to an overall bullish bias. Momentum and momentum-derived indicators are largely neutral and MACD is flat, while on-balance volume is constructive. Volatility is moderate with ATR near 4.8 percent, and the classic pivot is below the market, offering a nearby support reference. Technical takeaway: Strong Buy.
All signals
  • EMA (5 indicators)$30.85 - $44.85
    Buy
  • RSI (14)52.24
    Neutral
  • Stochastic %K (14, 3, 3)27.76
    Neutral
  • MACD Level (12, 26)0.26
    Neutral

Peers & Related Assets

TNGXTango Therapeutics, Inc.
$24+5.7%
NRIXNurix Therapeutics, Inc.
$26.26+0.5%
KODKodiak Sciences Inc.
$33.78-3.7%
XNCRXencor, Inc.
$24.94-1.5%
ANABAnaptysBio, Inc.
$55.7-1.6%
PHATPhathom Pharmaceuticals, Inc.
$8.67-8.1%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.